BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GVV858 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GVV858\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07288359-9062@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:GVV858: Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:GVV858\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Study of GVV858 as a Single Agent or in Combination With Endocrine Thera
 py in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumor
 s\nEstimated primary completion: 9 May 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gvv858#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/gvv858#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
